Fms -like tyrosine kinase 3 positive acute myeloid leukemia.

doi:10.1097/CCO.0000000000000993

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Fms -like tyrosine kinase 3 positive acute myeloid leukemia.

Current opinion in oncology - 1 Nov 2023

Isidori Alessandro, Visani Giuseppe, Ferrara Felicetto

Abstract excerpt

PURPOSE OF REVIEW: Fms -like tyrosine kinase 3 (FLT3) mutations are common in newly diagnosed patients with acute myeloid leukemia (AML). They are associated with a high risk of relapse. The identification of FLT3 mutations has important implications for the management of AML. FLT3 inhibitors have shown improved outcomes in FLT3-positive AML when used as a single agent in the salvage setting. However, the...

Topics

Humans
Antineoplastic Agents
Protein Kinase Inhibitors
fms-Like Tyrosine Kinase 3
Leukemia, Myeloid, Acute
Prognosis
Mutation

Source

Open in PubMed

Identifiers

PMID: 37820093
DOI: 10.1097/CCO.0000000000000993

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics